A practical reference on mass spectrometry: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-03. Anything still debated is marked as such rather than presented as settled.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Seven residues; tuftsin plus a Pro-Gly-Pro tail |
| Molecular formula | C33H57N11O9 | Commonly reported value for the free peptide |
| Monoisotopic mass | Roughly 751.4 Da | Average molecular mass near 751.9 Da |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Freely soluble in water | Also dissolves in saline and other polar solvents |
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.
Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
=== Pharmacodynamics === Iso-LSD shows significant affinity for serotonin receptors. It had an affinity (IC50Tooltip half-maximal inhibitory concentration) of about 200 nM for serotonin receptors in rat brain membranes. For comparison, LSD had an affinity of about 8 to 10 nM in the studies, while isoergine had an affinity of 100 to 200 nM and ergine (LSA) had an affinity of about 200 nM. Hence, iso-LSD showed about 10- to 30-fold lower affinity for serotonin receptors than LSD but had similar affinity for the receptors as ergine and isoergine. Despite these findings however, iso-LSD showed only 0.12% of the antiserotonergic activity of LSD (~1,000-fold lower in comparison) in the isolated rat uterus. In studies by David E. Nichols and colleagues, iso-LSD fully substituted for LSD in rodent drug discrimination tests. Full substitution occurred at a dose of 0.32 mg/kg and its ED50Tooltip median effective dose was 0.14 mg/kg, whereas the LSD training dose was 0.08 mg/kg. Iso-LSD was about 7 times less potent than LSD in terms of ED50 in this assay. In other studies, the drug had about 3.7% of the toxic potency of LSD in rabbits (presumably in terms of LD50Tooltip median lethal dose) and, unlike LSD, was not pyretogenic.
Flotufolastat (18F), sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The active ingredient is flotufolastat (18F). Flotufolastat (18F) was approved for medical use in the United States in May 2023.
Overtraining occurs when a person exceeds their body's ability to recover from strenuous exercise. Overtraining can be described as a point at which a person may have a decrease in performance or plateau as a result of failure to perform at a certain level or training-load consistently; a load which exceeds their recovery capacity. People who are overtrained cease making progress, and can even begin to lose strength and fitness. Overtraining is also known as chronic fatigue, burnout, and overstress in athletes. It is suggested that there are different forms of overtraining. Firstly, "monotonous program overtraining" suggests that repetition of the same movement, such as certain weight lifting and baseball batting, can cause performance plateau due to an adaption of the central nervous system, which results from a lack of stimulation. A second example of overtraining is described as "chronic overwork-type," wherein the subject may be training with too high intensity or high volume and not allowing sufficient recovery time for the body. Up to 10% of elite endurance athletes and 10% of American college swimmers are affected by overtraining syndrome (i.e., unexplained underperformance for approximately 2 weeks, even after having adequate resting time).
Litigation often begins and is resolved by member state courts. They interpret and apply EU law, and award remedies of compensation and restitution (remedying loss or stripping gains), injunctions and specific performance (making somebody stop or do something). If, however, the position in EU law appears unclear, member state courts can refer questions to the Court of Justice for a "preliminary ruling" on EU law's proper interpretation. TFEU article 267 says court "may" refer "if it considers" this "is necessary to enable it to give judgment", and "shall bring the matter before the Court" if there is no possibility for further appeal and remedy. Any "court or tribunal of a Member State" can refer. This is widely interpreted. It obviously (until Brexit) included bodies like the UK Supreme Court, a High Court, or an Employment Tribunal. In Vaassen v Beambtenfonds Mijnbedrijf the Court of Justice also held that a mining worker pension arbitration tribunal could make a reference. By contrast, and oddly, in Miles v European Schools the Court of Justice held that a Complaints Board of European Schools, set up under the international agreement, the European Schools Convention, could not refer because though it was a court, it was not "of a member state" (even though all member states had signed that Convention).
Sources: en.wikipedia.org
Newborn screening is the process of testing newborn babies for treatable genetic, endocrinologic, metabolic and hematologic diseases. The development of tandem mass spectrometry screening in the early 1990s led to a large expansion of potentially detectable congenital metabolic diseases that affect blood levels of organic acids. Small molecule analysis It has been shown that tandem mass spectrometry data is highly consistent across instrument and manufacturer platforms including quadrupole time-of-flight (QTOF) and Q Exactive instrumentation, especially at 20 eV.
The Druze Religious Authority in Suwayda announced it had reached a comprehensive agreement with the Syrian government to fully integrate the province within the Syrian state and reaffirm the state's sovereignty over the region. The agreement stipulates the restoration and activation of all government institutions in Suwayda. Additionally, the agreement provides for the withdrawal of army forces to their barracks, replacing them with internal security forces composed of local officers, the Syrian Ministry of Interior confirmed the ceasefire and the deployment of security checkpoints across the city as part of the reintegration process, Sheikh Hikmat al-Hijri issued a statement denying the existence of any agreement involving what he called "armed gangs falsely claiming to be the government." Addressing the people and "our heroic youth who defend the land, honor, and religion," the statement praised what he described as the "spirit of heroism and dignity" and urged continued resistance against the "criminal armed terrorist gangs," which he accused of committing murder, robbery, looting, and arson of homes, hospitals, and places of worship. The statement emphasized the importance of continuing "legitimate self-defense," calling for the struggle to continue "until the complete liberation of Suwayda Governorate from these gangs without conditions," presenting it as a national, humanitarian, and moral duty that admits no compromise.
== History == Viracor-IBT was created through the merger of two specialty diagnostic testing labs, Viracor Laboratories and IBT Laboratories. Founded by Dr. Konstance Knox and Dr. Donald Carrigan in Milwaukee County in 2000, Viracor was among the first to commercially offer real-time quantitative PCR assays to diagnose patients with Adenovirus, BK virus and JC virus, among others. Founded in 1983, IBT was the first laboratory to offer a test to definitively diagnose autoimmune causes of chronic hives and developed the first commercially available test to measure pneumococcal antibodies. On 1 July 2014, Ampersand Capital Partners completed the sale of Viracor-IBT Laboratories to Eurofins Scientific for $255 million. The company continued to be known as Viracor-IBT.
These strongly electrophilic NAIs allow for reactions with a wide range of nitrogen nucleophiles, including hindered and electron-deficient amines. An added benefit of the use of NMI as the base, due to its low pKa(H2O) of 7, is that the epimerization of labile stereogenic centers is minimized. The reaction by-products have high water solubility, facilitating reaction workup and isolation.
Similarly, in Asian adults homozygous for the hypoactive CYP2D6*10 allele, atomoxetine peak levels were about 1.5-fold higher and total exposure 2-fold higher compared to extensive metabolizers. There is little accumulation of atomoxetine with repeated administration in CYP2D6 extensive metabolizers, but significant accumulation in CYP2D6 poor metabolizers. The pharmacokinetics of atomoxetine, for instance elimination half-life, volume of distribution, and clearance, are similar with a single dose versus at steady state.
Sources: en.wikipedia.org
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.
No peptide with this exact sequence has been identified as an endogenous substance. It is a laboratory-designed analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The Pro-Gly-Pro extension has no known natural source.
Proline introduces conformational constraints that make a peptide less accessible to common peptidases. This is a standard stabilization strategy in peptide design. The added residues also increase the distance between the active tuftsin portion and typical cleavage sites.
Identity is confirmed by matching the retention time in reversed-phase chromatography against a reference standard and by measuring the molecular mass with mass spectrometry. Tandem mass spectrometry or amino acid analysis can verify the sequence of the seven residues. Because the peptide contains no aromatic amino acids, detection at 280 nm is not useful.